These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26717372)

  • 1. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment.
    Aydiner A; Sen F; Tambas M; Ciftci R; Eralp Y; Saip P; Karanlik H; Fayda M; Kucucuk S; Onder S; Yavuz E; Muslumanoglu M; Igci A
    Medicine (Baltimore); 2015 Dec; 94(52):e2341. PubMed ID: 26717372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature.
    El Zein D; Hughes M; Kumar S; Peng X; Oyasiji T; Jabbour H; Khoury T
    Clin Breast Cancer; 2017 Aug; 17(5):382-391. PubMed ID: 28529029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metaplastic breast cancer: Prognostic and therapeutic considerations.
    Corso G; Frassoni S; Girardi A; De Camilli E; Montagna E; Intra M; Bottiglieri L; Margherita De Scalzi A; Fanianos DM; Magnoni F; Invento A; Toesca A; Conforti F; Bagnardi V; Viale G; Colleoni MA; Veronesi P
    J Surg Oncol; 2021 Jan; 123(1):61-70. PubMed ID: 33047318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma.
    Li Y; Zhang N; Zhang H; Yang Q
    J Clin Pathol; 2019 Jun; 72(6):418-424. PubMed ID: 30872384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of outcomes between metaplastic and triple-negative breast cancer patients.
    Polamraju P; Haque W; Cao K; Verma V; Schwartz M; Klimberg VS; Hatch S; Niravath P; Butler EB; Teh BS
    Breast; 2020 Feb; 49():8-16. PubMed ID: 31675684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
    Lee J; Kim HH; Ro SM; Yang JH
    PLoS One; 2017; 12(2):e0171605. PubMed ID: 28234911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
    Wang S; Shi Y; Yuan Z; Wang X; Liu D; Peng R; Teng X; Qin T; Peng J; Lin G; Jiang X
    Med Oncol; 2012 Jun; 29(2):547-53. PubMed ID: 21528408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
    Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
    Mills MN; Yang GQ; Oliver DE; Liveringhouse CL; Ahmed KA; Orman AG; Laronga C; Hoover SJ; Khakpour N; Costa RLB; Diaz R
    Eur J Cancer; 2018 Jul; 98():48-58. PubMed ID: 29870876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics and prognosis of metaplastic breast cancer versus triple-negative invasive ductal carcinoma: a retrospective analysis.
    Yang X; Tang T; Zhou T
    World J Surg Oncol; 2023 Nov; 21(1):364. PubMed ID: 37996840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.
    Morgan E; Suresh A; Ganju A; Stover DG; Wesolowski R; Sardesai S; Noonan A; Reinbolt R; VanDeusen J; Williams N; Cherian MA; Li Z; Young G; Palettas M; Stephens J; Liu J; Luff A; Ramaswamy B; Lustberg M
    World J Surg Oncol; 2020 Jan; 18(1):11. PubMed ID: 31937323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metaplastic carcinoma of the breast: matched cohort analysis of recurrence and survival.
    Narayan P; Kostrzewa CE; Zhang Z; O'Brien DAR; Mueller BA; Cuaron JJ; Xu AJ; Bernstein MB; McCormick B; Powell SN; Khan AJ; Wen HY; Braunstein LZ
    Breast Cancer Res Treat; 2023 Jun; 199(2):355-361. PubMed ID: 36976395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
    Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
    Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
    Liu YL; Saraf A; Catanese B; Lee SM; Zhang Y; Connolly EP; Kalinsky K
    Breast Cancer Res Treat; 2018 Jan; 167(1):277-288. PubMed ID: 28948418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
    Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
    Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
    Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.